STTK, US82024L1035

Shattuck Labs stock: Shattuck Labs presents two UEG posters for Shattuck Labs stock

Published on 10/24/2026 at 05:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 13, 2026 release detailed two UEG posters linked to SL-325 and SL-846. Shattuck Labs stock reported a USD 15.15 million GAAP loss.

Clinical program and analyst targets

Shattuck Labs announced two UEG poster presentations on October 13, 2026.
The company reported a USD 15.15 million GAAP net loss for the second quarter of 2026.
UBS initiated coverage with a USD 17.00 price target on October 11, 2026.

STTK, US82024L1035, Illustration mit AI erstellt.

Shattuck Labs (ISIN US82024L1035) detailed two poster presentations for United European Gastroenterology Week on October 13, 2026, covering SL-846 and immune-complex research. GlobeNewswire reported that the presentations were scheduled during the October 17 to October 20 congress in Barcelona.

Two posters broaden the program

The company presented SL-846, a dual-receptor DR3 x IL23RA bispecific antibody, on October 19, 2026. A second ePoster covering TL1A immune complexes was available throughout the congress from October 17 to October 20, 2026, according to GlobeNewswire.

What does the pipeline mean?

Shattuck is moving SL-325 into the RECEPTIVE-HS1 Phase 2 trial for moderate to severe hidradenitis suppurativa. The study is expected to enroll approximately 150 patients across two dose levels and placebo, with a 16-week controlled treatment period and data expected in the first half of 2028, Yahoo Finance reported on October 1, 2026.

Three events set the sequence

On October 1, 2026, Shattuck announced the Phase 2 plan for SL-325 and appointed Shoba Ravichandran as senior vice president of clinical development, with the study designed for approximately 150 patients, according to Yahoo Finance. On October 11, 2026, UBS initiated coverage with a USD 17.00 target and a Buy rating, as reported by Markets Insider. On October 13, 2026, Shattuck announced two UEG posters through GlobeNewswire.

Clinical dates remain ahead

The company said an investigational new drug submission was expected in October 2026, while Week 16 data were expected in the first half of 2028, according to Yahoo Finance. Those dates leave clinical execution as the central valuation reference for the biotechnology company.

Losses shape the valuation

Shattuck reported a USD 15.15 million GAAP net loss for the second quarter of 2026, compared with a USD 12.46 million loss in the year-earlier quarter, according to Markets Insider. The operating profile therefore remains tied to trial progress rather than product revenue.

Frankfurt price remains the marker

The last Frankfurt price was EUR 4.92 on October 23, 2026 at 8:03 a.m. CEST. On Nasdaq, the stock was last at USD 5.49 on October 23, 2026 at 4:00 p.m. ET, with a market capitalization of USD 551.0 million and a 52-week range of USD 1.72 to USD 8.33.